ClinicalTrials.gg

Crohn Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,994 studies for Crohn Disease across more than 10 countries. 478 are recruiting or about to start. 1,400 of them are mainly about Crohn Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,121 studies for Crohn Disease. How that becomes 1,993 here

This page counts the studies the registry files under Crohn Disease, and those it files under no condition that list Crohn Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,121Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −19List Crohn Disease as a condition, but the registry did not file them under itMost often written as “Pediatric Crohn's Disease” (5), “Pediatric Crohns Disease” (4), and “Perianal Crohn Disease” (2). The registry filed them under other conditions only, most often Pediatric Crohn's disease (5) and Inflammatory Bowel Diseases (4).
  3. −109Match it another way74 name it in the title, 3 in a keyword, and 32 by a synonym or other text the search reads.
  4. 1,993The count on this page42 of them list Crohn Disease in their own words; the registry filed them under no condition.

Status

Completed
895
Recruiting
353
Status unknown
233
Terminated
212
Not yet recruiting
101
Active, not recruiting
91

Phase

Phase 2
325
Phase 3
243
Phase 1
172
Phase 4
153
Early Phase 1
20

Where

United States
660
France
316
Canada
286
Germany
217
United Kingdom
217
Italy
205

Who develops what

Add Crohn Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 38 programs from 25 companies, 29 with this as their studies’ main aim; 8 with a live phase 3 study; 15 primary completions in the next 12 months. Compare Johnson & Johnson, AbbVie and Sanofi here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
UstekinumabRecent, limited
Evidence
  • NCT06045754 · Takeda · Phase 4 · live · background · “Ustekinumab” · registered Sep 2023
  • NCT04978493 · Boehringer Ingelheim · Phase 2 · background · “Ustekinumab” · registered Jul 2021
  • NCT04524611 · AbbVie · Phase 3 · live · comparator · “Ustekinumab” · registered Aug 2020
  • NCT03926130 · Eli Lilly and Company · Phase 3 · comparator · “Ustekinumab” · registered Apr 2019
Johnson & Johnson86% of its industry studiesUS: Johnson & Johnson (FDA 2009) + 7 othersEU: Johnson & Johnson (EMA 2009) + 11 others11 study
AdalimumabRecent, limited
Evidence
  • NCT06045754 · Takeda · Phase 4 · live · background · “Adalimumab” · registered Sep 2023
  • NCT04655807 · Johnson & Johnson · Phase 2 · background · “Adalimumab” · registered Nov 2020
  • NCT04643483 · UCB S.A. · Phase 3 · comparator · “Adalimumab” · registered Nov 2020
  • NCT03759288 · AstraZeneca · Phase 3 · comparator · “Humira®” · registered Nov 2018
  • NCT03464136 · Johnson & Johnson · Phase 3 · comparator · “Adalimumab (40 mg)” · registered Mar 2018
Abbott41% of its industry studiesUS: Amgen (FDA 2016) + 3 othersEU: AbbVie (EMA 2003) + 10 others11 study
upadacitinibRecent, limited
Evidence
  • NCT06227910 · Takeda · Phase 3 · live · background · “Upadacitinib” · registered Jan 2024
AbbVie95% of its industry studiesUS: AbbVie (FDA 2019)EU: AbbVie (EMA 2019)11 study

3 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
risankizumabApproved: US 2019 · EU 2019☆ Track4 live phase-3 studies: NCT05995353, NCT03105102, NCT04524611AbbVie
guselkumabApproved: US 2017 · EU 2017☆ Track7 live phase-3 studies: NCT05923073, NCT06408935, NCT05347095Johnson & Johnson
TirzepatideApproved: US 2022 · EU 2022☆ Track1 live phase-3 study: NCT06937099Eli Lilly and Company
JNJ-78934804☆ Track1 live phase-3 study: NCT07577843Johnson & Johnson
icotrokinraApproved: US 2026☆ Track1 live phase-3 study: NCT07196722Johnson & Johnson

The 5 in phase 3 with the nearest primary completion, of 38 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (15)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 17 Dec 2026 est.brivekimig · Sanofi · Phase 2 main aimNCT06958536 A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease — primary endpoint: Percentage of participants who achieve endoscopic response at Week 16 · 99 enrolled
  • 31 Dec 2026 est.afimkibart · Hoffmann-La Roche · Phase 2 main aimNCT05910528 Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease — primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAE), Serious Adverse Events (SAE) and AE Leading to Discontinuation · 21 enrolled
  • 17 Feb 2027 est.zasocitinib · Takeda · Phase 2 main aimNCT06233461 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — primary endpoint: Percentage of Participants With Endoscopic Response Based on Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 12 · 268 enrolled

12 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Crohn Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 5 open · JAK inhibitors 5 open · Tyrosine kinase inhibitors (TKIs) 5 open · Corticosteroids 4 open · Alkylating agents 4 open

Coming up

171studies finish main data collection within a year12 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger. 95 (27%) take children under 18. 9 (3%) are for women only and 3 (1%) for men only; 56 (16%) take healthy volunteers.

Recruiting studies that take each age, of 353
AgeWomenMen
1061 (17%)59 (17%)
18328 (93%)322 (91%)
30312 (88%)306 (87%)
40311 (88%)306 (87%)
50308 (87%)302 (86%)
65295 (84%)291 (82%)
75249 (71%)244 (69%)
85173 (49%)168 (48%)

Across all 1,994 studies, recruiting or not: 43% stop at 75 or younger and 24% at 65; 24% take children; 2% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Crohn Disease studies take

Of 88 phase 3 interventional studies under Crohn Disease, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 122 mo10–41 · 61 studies16 mo5–28 · 33 studies—
Phase 234 mo23–51 · 83 studies33 mo20–45 · 56 studies—
Phase 349 mo36–69 · 88 studies46 mo35–69 · 70 studies—
Phase 456 mo35–68 · 70 studies—56 mo44–71 · 54 studies
Interventional, no phase45 mo21–65 · 301 studies—46 mo22–67 · 289 studies
Observational41 mo29–88 · 304 studies36 mo28–60 · 73 studies47 mo32–101 · 231 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,994. Browse all 1,994 → or search them.